Medicine Questions
Report an Adverse Event
Investors
Contact
North America South America
Asia
Middle East Africa Australia
Europe

Disclosures

Introduction

Gilead believes that there is strength through partnership. Collaborations of all kinds - with partners in science, academia, business and local communities - are central to our work. Partnerships enhance our ability to develop innovative medicines and deliver them to people as efficiently as possible.

Healthcare professionals, other relevant decision makers and healthcare organizations with whom we work provide valuable, independent and expert knowledge derived from their clinical and management experience. This expertise makes an important contribution to our efforts to improve the quality of patient care, with benefits for individuals and society at large. We believe healthcare professionals, other relevant decision makers and healthcare organizations should be fairly compensated for the legitimate expertise and services they provide.

We are fully committed to compliance with healthcare spend transparency requirements which require disclosure of payments and transfers of value made to healthcare professionals, other relevant decision makers and healthcare organizations. We believe this is the right approach for industry and enhances stakeholder trust.

In line with local Transparency Reporting requirements, Gilead is disclosing its interactions with healthcare professionals and healthcare organizations in the following reports for European countries, supported by either the Gilead EFPIA Methodological Note or by a locally adapted one.

Inquiries about any of these reports should be directed here.

Gilead Sciences 2023 EFPIA Disclosure Code - Self-Certification letter

Gilead Sciences EFPIA Disclosure Code 2022 Self-certification Scheme Letter

Gilead Sciences EFPIA Disclosure Code 2021 Self-certification Scheme Letter

Gilead Sciences EFPIA Methodological Note 2022

Gilead Sciences EFPIA Methodological Note 2021

Gilead Sciences EFPIA Methodological Note 2020

Bosnia Herzegovina

Gilead Sciences Bosnia & Herzegovina EFPIA Report 2021 (in English)

Gilead Sciences Bosnia & Herzegovina EFPIA Report 2020 (in English)

Gilead Sciences Bosnia & Herzegovina EFPIA Report 2019 (in English)

Czech Republic

As of 2020, the Czech affiliate (Gilead Sciences s.r.o.) is a member of the Czech Association of Innovative Pharmaceutical Industry (AIFP). In line with our obligations to disclose payments and transfers of value, disclosure information covering the previous calendar year is published on the AIFP Disclosure platform www.transparentnispoluprace.cz annually on or around June 30. Find disclosure information for previous years below. 

Get more information about Gilead operations in the Czech Republic and Slovakia

Gilead Sciences Czech Republic Methodological Note 2021 (in English)

Gilead Sciences Czech Republic Methodological Note 2021 (in Czech)

Gilead Sciences Czech Republic Methodological Note 2020 (in English)

Gilead Sciences Czech Republic Methodological Note 2020 (in Czech)

Gilead Sciences Czech Republic EFPIA Report 2019

Gilead Sciences Czech Republic Methodological Note 2019 (in Czech)

Gilead Sciences Czech Republic Methodological Note 2019 (in English)

Ireland

In line with the Irish Pharmaceutical Healthcare Association code, transfers for value made to HCPs, HCOs based in Ireland, are uploaded on https://www.transferofvalue.ie on or around 30 of June covering the previous calendar year.

Enquiries about the disclosed transfers of value should be directed here.

Netherlands

In line with the Commissie Geneesmiddelen Reclame (CGR) code, transfers for value made to HCPs, HCOs and Patient Organizations based in Netherlands, are uploaded on www.transparantieregister.nl on or around 31st of May covering the previous calendar year.

R&D spend is disclosed in aggregate on the affiliate’s web page.

Enquiries about the disclosed transfers of value should be directed here.

North Macedonia

Gilead Sciences North Macedonia EFPIA Report 2021 (in Macedonian)

Gilead Sciences North Macedonia EFPIA Report 2020 (in Macedonian)

Gilead Sciences North Macedonia EFPIA Report 2019 (in Macedonian)

Portugal

In line with our obligations to disclose payments and transfers of value, disclosure information in Portugal is disclosed in the Portuguese Medicines Agency transparency platform (Plataforma de Comunicações - Transparência e Publicidade do INFARMED) within 30 days of payment or transfer of value date. Click here to access the platform. To access the disclosed information, insert “Gilead Sciences.” General enquiries about the disclosure should be directed here.

Slovakia

As of 2016, in line with our legal obligations to disclose payments and transfers of value, disclosure information in Slovakia is published on the National Health Information Center platform nczisk.sk every 6 months. Click here to see reports. Enquiries about the disclosed transfers of value should be directed here.

European Distributor Market Countries

2021 EDM Patient Organisation Report Publication